ROKIT Healthcare will push to list its U.S. subsidiary "ROKIT America" on Nasdaq.
ROKIT Healthcare said on the 16th that its U.S. subsidiary ROKITAMERICA,INC. filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on the 15th local time. The goal is to list next month.
The company said it plans to use the listing to expand its business scope from North America to South America. In particular, it will strengthen research and development (R&D) cooperation with major medical and research institutions, including Harvard Medical School, with the United States as a key base.
ROKIT Healthcare cited the following listing objectives: ◇ global expansion of its organ regeneration platform and anti-aging business ◇ accelerated growth of subsidiaries ◇ enhanced corporate value through synergies with the parent company.
A company official said, "This listing is a process to verify ROKIT America's technological strength and independent management base in the U.S. capital market," adding, "Based on the funds raised, we will expand the organ regeneration platform business and enhance shareholder value as a global healthcare corporation."